Biocon
Biocon Biologics Limited, based in Bengaluru, India, is a subsidiary of Biocon Limited and specializes in the development and commercialization of biosimilars and novel biologics. Established in 2016, the company focuses on producing high-quality, affordable biosimilars to improve patient access to innovative therapies. Its product offerings include recombinant human insulin, insulin analogs, monoclonal antibodies, and therapeutic proteins, targeting diseases such as diabetes, cancer, and autoimmune conditions. Biocon Biologics operates across various global markets, including the U.S. and Europe, while also providing integrated contract research and manufacturing services through its subsidiary, Syngene. The company is committed to addressing the humanitarian need for essential drugs and aims to deliver cost-effective biopharmaceutical solutions through its advanced manufacturing capabilities and scientific expertise.
Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates our development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.
Fusion Microfinance Private Limited is a non-banking financial company based in New Delhi, specializing in providing micro-credit services to women entrepreneurs in rural and semi-urban regions of India. Established in 1994, the company began its Greenfield operations in January 2010 and expanded its reach by acquiring the microfinance division of Aajeevika, which had a loan book of Rs 6.3 million and 1,280 members at the time of acquisition. Fusion Microfinance focuses on facilitating the establishment and growth of small businesses by offering micro-loans and life insurance products. As of March 31, 2019, the company operated through a network of 504 branches across less penetrated areas in North Central India, including Madhya Pradesh, Uttarakhand, Uttar Pradesh, Delhi, and Haryana.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.